520.57
-6.09 (-1.16%)
| Penutupan Terdahulu | 526.66 |
| Buka | 517.00 |
| Jumlah Dagangan | 471,703 |
| Purata Dagangan (3B) | 628,256 |
| Modal Pasaran | 41,865,232,384 |
| Harga / Pendapatan (P/E TTM) | 48.07 |
| Harga / Pendapatan (P/E Ke hadapan) | 46.08 |
| Harga / Jualan (P/S) | 13.35 |
| Harga / Buku (P/B) | 35.98 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2025 |
| Margin Keuntungan | 22.76% |
| Margin Operasi (TTM) | 31.70% |
| EPS Cair (TTM) | 10.82 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 3.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 3.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 73.16% |
| Nisbah Semasa (MRQ) | 1.16 |
| Aliran Tunai Operasi (OCF TTM) | 968.38 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 761.15 M |
| Pulangan Atas Aset (ROA TTM) | 22.98% |
| Pulangan Atas Ekuiti (ROE TTM) | 59.33% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | IDEXX Laboratories, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 2.25 |
|
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.67% |
| % Dimiliki oleh Institusi | 97.51% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 765.00 (Morgan Stanley, 46.95%) | Beli |
| Median | 675.00 (29.67%) | |
| Rendah | 540.00 (Stifel, 3.73%) | Pegang |
| Purata | 656.00 (26.02%) | |
| Jumlah | 3 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 609.43 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 15 Aug 2025 | 765.00 (46.95%) | Beli | 650.84 |
| Piper Sandler | 11 Aug 2025 | 700.00 (34.47%) | Pegang | 652.11 |
| JP Morgan | 04 Aug 2025 | 675.00 (29.67%) | Beli | 682.78 |
| Leerink Partners | 17 Jul 2025 | 600.00 (15.26%) | Beli | 518.71 |
| Stifel | 02 Jul 2025 | 540.00 (3.73%) | Pegang | 542.71 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Sep 2025 | Pengumuman | IDEXX Laboratories to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference |
| 04 Aug 2025 | Pengumuman | IDEXX Laboratories Announces Second Quarter Results |
| 30 Jul 2025 | Pengumuman | IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals |
| 10 Jul 2025 | Pengumuman | IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors |
| 24 Jun 2025 | Pengumuman | IDEXX Laboratories to Release 2025 Second Quarter Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |